Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Pharm Res. 2015 Jun 16;32(11):3746–3755. doi: 10.1007/s11095-015-1736-9

Fig. 2.

Fig. 2

T2-weighted MRI of MDA-MB-231/luc tumors before and after the intravenous administration of SPIONs-based contrast agents. A. SPIONs; B. Lip(Gd/Fe); C. scVEGF-Lip(Gd/Fe). Each yellow broken line represents a region-of-interest (ROI), in the MDA-MB-231/luc tumor. TE=35 ms.